Literature DB >> 24649034

Combined effects of simvastatin and fibroblast growth factor-2 on the proliferation and differentiation of preosteoblasts.

Jun-Beom Park1.   

Abstract

Simvastatin reportedly promotes osteoblastic and inhibits osteoclastic activity. It increases bone formation when injected subcutaneously over the calvaria in mice. It also increases cancellous bone volume in rats following oral administration. Fibroblast growth factor-2 (FGF-2), a member of the FGF family, is expressed by cells of the osteoblastic lineage. FGF-2 promotes osteoblast proliferation and it is secreted during the healing process of fractures or at bone surgery sites. FGF-2 reportedly regulates bone formation and osteoblast differentiation. In this study, the combined effects of simvastatin and FGF-2 on the proliferation and differentiation of preosteoblasts were investigated and an alkaline phosphatase (ALP) activity test was performed to assess the differentiation. Moreover, the expression of proteins associated with bone formation were measured using western blot analysis. The results demonstrated that the protein content of the cultures grown in osteogenic differentiation media in the presence of FGF-2 at a concentration of 20 ng/ml was higher compared to that of the untreated control cultures. ALP activity was decreased when cells were treated with FGF-2 (2 and 20 ng/ml) and increased when cells were treated with simvastatin. The cultures grown in the presence of 1 μM of simvastatin and 2 ng/ml of FGF-2 exhibited increased ALP activity when compared to that in the 2 ng/ml FGF-2-only group. The combination of 1.0 μM simvastatin and 2 ng/ml FGF-2 achieved a higher estrogen receptor-α expression compared to the 2 ng/ml FGF-2-only group. Within the limits of this study, simvastatin enhanced osteoblast differentiation. However, the combined treatment with simvastatin and FGF-2 did not exert synergistic effects on osteoblast differentiation under the current experimental conditions. Future studies are required to evaluate divergent conditions and determine the selective timing and optimal dosage for the delivery of the agents.

Entities:  

Keywords:  differentiation; fibroblast growth factor 2; osteoblast; proliferation; simvastatin

Year:  2013        PMID: 24649034      PMCID: PMC3917103          DOI: 10.3892/br.2013.137

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  14 in total

Review 1.  Molecular and cellular determinants of estrogen receptor alpha expression.

Authors:  Joseph J Pinzone; Holly Stevenson; Jeannine S Strobl; Patricia E Berg
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

2.  Effects of fibroblast growth factor 2 on osteoblastic proliferation and differentiation by regulating bone morphogenetic protein receptor expression.

Authors:  Jun-Beom Park
Journal:  J Craniofac Surg       Date:  2011-09       Impact factor: 1.046

3.  The effects of dexamethasone, ascorbic acid, and β-glycerophosphate on osteoblastic differentiation by regulating estrogen receptor and osteopontin expression.

Authors:  Jun-Beom Park
Journal:  J Surg Res       Date:  2010-10-08       Impact factor: 2.192

Review 4.  Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation.

Authors:  Y Ishida; J N Heersche
Journal:  J Bone Miner Res       Date:  1998-12       Impact factor: 6.741

5.  Stimulation of bone formation in vitro and in rodents by statins.

Authors:  G Mundy; R Garrett; S Harris; J Chan; D Chen; G Rossini; B Boyce; M Zhao; G Gutierrez
Journal:  Science       Date:  1999-12-03       Impact factor: 47.728

6.  Low dose of doxycyline promotes early differentiation of preosteoblasts by partially regulating the expression of estrogen receptors.

Authors:  Jun-Beom Park
Journal:  J Surg Res       Date:  2012-04-21       Impact factor: 2.192

7.  Effects of dexamethasone on proliferation, activity, and cytokine secretion of normal human bone marrow stromal cells: possible mechanisms of glucocorticoid-induced bone loss.

Authors:  C H Kim; S L Cheng; G S Kim
Journal:  J Endocrinol       Date:  1999-09       Impact factor: 4.286

8.  Fibroblast growth factor 2 inhibits up-regulation of bone morphogenic proteins and their receptors during osteoblastic differentiation of human mesenchymal stem cells.

Authors:  Emmanuel Biver; Anne-Sophie Soubrier; Cyril Thouverey; Bernard Cortet; Odile Broux; Joseph Caverzasio; Pierre Hardouin
Journal:  Biochem Biophys Res Commun       Date:  2012-10-05       Impact factor: 3.575

9.  Fibroblast growth factor 2 inhibits bone morphogenetic protein 9-induced osteogenic differentiation of mesenchymal stem cells by repressing Smads signaling and subsequently reducing Smads dependent up-regulation of ALK1 and ALK2.

Authors:  Tao Song; Wenjuan Wang; Jing Xu; Dan Zhao; Qian Dong; Li Li; Xue Yang; Xinglian Duan; Yiwen Liang; Yan Xiao; Jin Wang; Juanwen He; Ming Tang; Jian Wang; Jinyong Luo
Journal:  Int J Biochem Cell Biol       Date:  2013-05-13       Impact factor: 5.085

Review 10.  The use of simvastatin in bone regeneration.

Authors:  Jun-Beom Park
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.